Trial Outcomes & Findings for A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (NCT NCT02594384)
NCT ID: NCT02594384
Last Updated: 2024-08-22
Results Overview
MTD was determined by testing increasing doses up to 125 mg twice a day or 75 mg three times a day orally on dose escalation cohorts with 3 to 6 participants each. In the dose escalation, the cohort sizes of 3 to 6 subjects allow evaluation of regimen safety using a standard definition of MTD (ie, the highest starting dose associated with DLT in \<33% of subjects during the first cycle of therapy) when administered continuously (daily administration) and then when administered intermittently (repeated courses of 3 days on and 4 days off).
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
62 participants
Primary outcome timeframe
28 days
Results posted on
2024-08-22
Participant Flow
This study was conducted at 12 study centers in the United States, 11 of which enrolled subjects to the trial.
Participant milestones
| Measure |
LAM-002A Continuous Monotherapy - 50 mg BID
All participants took 50 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 75 mg TID
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg BID
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
8
|
5
|
4
|
3
|
20
|
12
|
7
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
0
|
|
Overall Study
NOT COMPLETED
|
3
|
8
|
5
|
4
|
3
|
19
|
9
|
7
|
Reasons for withdrawal
| Measure |
LAM-002A Continuous Monotherapy - 50 mg BID
All participants took 50 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 75 mg TID
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg BID
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
Disease Progression
|
3
|
7
|
0
|
2
|
2
|
12
|
5
|
5
|
|
Overall Study
Adverse Event
|
0
|
1
|
4
|
1
|
0
|
6
|
1
|
1
|
|
Overall Study
Withdrawal by Subject
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
|
Overall Study
Progressive Leukocytosis
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Lack of Efficacy
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Overall Study
Substantial noncompliance
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
Baseline Characteristics
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
Baseline characteristics by cohort
| Measure |
LAM-002A Continuous Monotherapy - 50 mg BID
n=3 Participants
All participants took 50 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
n=8 Participants
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
n=5 Participants
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 75 mg TID
n=4 Participants
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg BID
n=3 Participants
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg
n=20 Participants
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
n=12 Participants
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
n=7 Participants
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
Total
n=62 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|
|
Age, Customized
Age Category · <65 years
|
2 Participants
n=39 Participants
|
3 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
9 Participants
n=19 Participants
|
7 Participants
n=147 Participants
|
2 Participants
n=193 Participants
|
24 Participants
|
|
Age, Customized
Age Category · ≥65 years
|
1 Participants
n=39 Participants
|
5 Participants
n=41 Participants
|
4 Participants
n=35 Participants
|
4 Participants
n=31 Participants
|
3 Participants
n=146 Participants
|
11 Participants
n=19 Participants
|
5 Participants
n=147 Participants
|
5 Participants
n=193 Participants
|
38 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=39 Participants
|
5 Participants
n=41 Participants
|
4 Participants
n=35 Participants
|
2 Participants
n=31 Participants
|
2 Participants
n=146 Participants
|
9 Participants
n=19 Participants
|
4 Participants
n=147 Participants
|
3 Participants
n=193 Participants
|
30 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=39 Participants
|
3 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
2 Participants
n=31 Participants
|
1 Participants
n=146 Participants
|
11 Participants
n=19 Participants
|
8 Participants
n=147 Participants
|
4 Participants
n=193 Participants
|
32 Participants
|
|
Race/Ethnicity, Customized
Race · White
|
3 Participants
n=39 Participants
|
6 Participants
n=41 Participants
|
4 Participants
n=35 Participants
|
3 Participants
n=31 Participants
|
3 Participants
n=146 Participants
|
16 Participants
n=19 Participants
|
11 Participants
n=147 Participants
|
7 Participants
n=193 Participants
|
53 Participants
|
|
Race/Ethnicity, Customized
Race · Black/African American
|
0 Participants
n=39 Participants
|
1 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
1 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
1 Participants
n=19 Participants
|
1 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
4 Participants
|
|
Race/Ethnicity, Customized
Race · Other
|
0 Participants
n=39 Participants
|
1 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
3 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
5 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Not Hispanic/Latino
|
3 Participants
n=39 Participants
|
8 Participants
n=41 Participants
|
5 Participants
n=35 Participants
|
3 Participants
n=31 Participants
|
3 Participants
n=146 Participants
|
16 Participants
n=19 Participants
|
12 Participants
n=147 Participants
|
7 Participants
n=193 Participants
|
57 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Hispanic/Latino
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
1 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
4 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
5 Participants
|
|
Eastern Cooperative Oncology Group (ECOG) Performance Status
0, fully active, able to carry on all predisease performance without restrictions
|
0 Participants
n=39 Participants
|
5 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
1 Participants
n=31 Participants
|
1 Participants
n=146 Participants
|
7 Participants
n=19 Participants
|
3 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
18 Participants
|
|
Eastern Cooperative Oncology Group (ECOG) Performance Status
1, restricted in physically strenuous activity but ambulatory and able to do light or sedentary work
|
3 Participants
n=39 Participants
|
3 Participants
n=41 Participants
|
3 Participants
n=35 Participants
|
2 Participants
n=31 Participants
|
2 Participants
n=146 Participants
|
11 Participants
n=19 Participants
|
9 Participants
n=147 Participants
|
6 Participants
n=193 Participants
|
39 Participants
|
|
Eastern Cooperative Oncology Group (ECOG) Performance Status
2, ambulatory and capable of all self-care but unable to work. Up more than 50% of waking hours
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
1 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
2 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
4 Participants
|
|
Eastern Cooperative Oncology Group (ECOG) Performance Status
3, capable of only limited self-care, confined to bed or chair more than 50% of waking hours
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
1 Participants
n=193 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: 28 daysPopulation: Full analysis set=All subjects who receive ≥1 dose of study drug.
MTD was determined by testing increasing doses up to 125 mg twice a day or 75 mg three times a day orally on dose escalation cohorts with 3 to 6 participants each. In the dose escalation, the cohort sizes of 3 to 6 subjects allow evaluation of regimen safety using a standard definition of MTD (ie, the highest starting dose associated with DLT in \<33% of subjects during the first cycle of therapy) when administered continuously (daily administration) and then when administered intermittently (repeated courses of 3 days on and 4 days off).
Outcome measures
| Measure |
All Participants
n=40 Participants
All participants who received at least 1 dose of LAM-002A, either at 50 mg BID, 100 mg BID, 150 mg BID, 75 mg TID, or 125 mg BID.
|
LAM-002A Continuous Monotherapy - 75 mg TID
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg BID
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
|---|---|---|---|---|---|---|---|---|
|
Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A
|
125 mg BID
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 8 daysPopulation: The PK population included all evaluable subjects who were dosed and had sufficient concentration-time data to estimate ≥1 of the planned PK parameters, as determined by the study pharmacokineticist.
Evaluation of the peak plasma concentration (Cmax) of LAM-002A and its metabolites in plasma on Day 1 and Day 8.
Outcome measures
| Measure |
All Participants
n=3 Participants
All participants who received at least 1 dose of LAM-002A, either at 50 mg BID, 100 mg BID, 150 mg BID, 75 mg TID, or 125 mg BID.
|
LAM-002A Continuous Monotherapy - 75 mg TID
n=3 Participants
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
n=8 Participants
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg BID
n=6 Participants
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
n=5 Participants
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg
n=3 Participants
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
|---|---|---|---|---|---|---|---|---|
|
Peak Plasma Concentration (Cmax) of LAM-002A
STA-6048 - Day 8
|
60.6 ng/mL
Standard Deviation 32.0
|
154 ng/mL
Standard Deviation 113
|
161 ng/mL
Standard Deviation 43.0
|
122 ng/mL
Standard Deviation 81.7
|
116 ng/mL
Standard Deviation 87.4
|
140 ng/mL
|
—
|
—
|
|
Peak Plasma Concentration (Cmax) of LAM-002A
Apilimod - Day 1
|
117 ng/mL
Standard Deviation 69.6
|
158 ng/mL
Standard Deviation 61.6
|
263 ng/mL
Standard Deviation 168
|
207 ng/mL
Standard Deviation 82.4
|
243 ng/mL
Standard Deviation 76.1
|
280 ng/mL
Standard Deviation 135
|
—
|
—
|
|
Peak Plasma Concentration (Cmax) of LAM-002A
Apilimod - Day 8
|
140 ng/mL
Standard Deviation 95.1
|
339 ng/mL
Standard Deviation 215
|
331 ng/mL
Standard Deviation 273
|
331 ng/mL
Standard Deviation 287
|
369 ng/mL
Standard Deviation 90.5
|
108 ng/mL
|
—
|
—
|
|
Peak Plasma Concentration (Cmax) of LAM-002A
STA-5908 - Day 1
|
112 ng/mL
Standard Deviation 85.0
|
114 ng/mL
Standard Deviation 71.6
|
215 ng/mL
Standard Deviation 88.6
|
144 ng/mL
Standard Deviation 92.5
|
196 ng/mL
Standard Deviation 142
|
207 ng/mL
Standard Deviation 135
|
—
|
—
|
|
Peak Plasma Concentration (Cmax) of LAM-002A
STA-5908 - Day 8
|
103 ng/mL
Standard Deviation 43.7
|
239 ng/mL
Standard Deviation 195
|
278 ng/mL
Standard Deviation 137
|
234 ng/mL
Standard Deviation 173
|
240 ng/mL
Standard Deviation 99.7
|
113 ng/mL
|
—
|
—
|
|
Peak Plasma Concentration (Cmax) of LAM-002A
STA-5944 - Day 1
|
209 ng/mL
Standard Deviation 145
|
243 ng/mL
Standard Deviation 124
|
346 ng/mL
Standard Deviation 131
|
281 ng/mL
Standard Deviation 125
|
369 ng/mL
Standard Deviation 306
|
466 ng/mL
Standard Deviation 247
|
—
|
—
|
|
Peak Plasma Concentration (Cmax) of LAM-002A
STA-5944 - Day 8
|
188 ng/mL
Standard Deviation 101
|
436 ng/mL
Standard Deviation 334
|
439 ng/mL
Standard Deviation 215
|
383 ng/mL
Standard Deviation 225
|
391 ng/mL
Standard Deviation 9.90
|
260 ng/mL
|
—
|
—
|
|
Peak Plasma Concentration (Cmax) of LAM-002A
STA-6048 - Day 1
|
63.2 ng/mL
Standard Deviation 40.2
|
59.9 ng/mL
Standard Deviation 54.0
|
136 ng/mL
Standard Deviation 64.2
|
90.0 ng/mL
Standard Deviation 58.6
|
131 ng/mL
Standard Deviation 134
|
145 ng/mL
Standard Deviation 66.0
|
—
|
—
|
SECONDARY outcome
Timeframe: 8 daysPopulation: The PK population included all evaluable subjects who were dosed and had sufficient concentration-time data to estimate ≥1 of the planned PK parameters, as determined by the study pharmacokineticist.
Evaluation of the Area under the concentration-time curve from time-zero to the time of the last quantifiable concentration (AUClast) of LAM-002ALAM-002A and its metabolites in plasma on Day 1 and Day 8.
Outcome measures
| Measure |
All Participants
n=3 Participants
All participants who received at least 1 dose of LAM-002A, either at 50 mg BID, 100 mg BID, 150 mg BID, 75 mg TID, or 125 mg BID.
|
LAM-002A Continuous Monotherapy - 75 mg TID
n=3 Participants
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
n=8 Participants
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg BID
n=6 Participants
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
n=5 Participants
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg
n=3 Participants
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
|---|---|---|---|---|---|---|---|---|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
Apilimod - Day 1
|
238 h*ng/mL
Standard Deviation 88.1
|
583 h*ng/mL
Standard Deviation 290
|
515 h*ng/mL
Standard Deviation 221
|
562 h*ng/mL
Standard Deviation 234
|
700 h*ng/mL
Standard Deviation 290
|
777 h*ng/mL
Standard Deviation 437
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
Apilimod - Day 8
|
374 h*ng/mL
Standard Deviation 119
|
1040 h*ng/mL
Standard Deviation 483
|
1130 h*ng/mL
Standard Deviation 930
|
1290 h*ng/mL
Standard Deviation 1040
|
1060 h*ng/mL
Standard Deviation 85.7
|
563 h*ng/mL
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
STA-5944 - Day 1
|
542 h*ng/mL
Standard Deviation 214
|
1020 h*ng/mL
Standard Deviation 659
|
1120 h*ng/mL
Standard Deviation 550
|
1180 h*ng/mL
Standard Deviation 587
|
1590 h*ng/mL
Standard Deviation 1420
|
1700 h*ng/mL
Standard Deviation 843
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
STA-5908 - Day 1
|
312 h*ng/mL
Standard Deviation 156
|
526 h*ng/mL
Standard Deviation 291
|
762 h*ng/mL
Standard Deviation 371
|
625 h*ng/mL
Standard Deviation 419
|
936 h*ng/mL
Standard Deviation 734
|
968 h*ng/mL
Standard Deviation 547
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
STA-6048 - Day 8
|
308 h*ng/mL
Standard Deviation 164
|
1040 h*ng/mL
Standard Deviation 780
|
959 h*ng/mL
Standard Deviation 343
|
746 h*ng/mL
Standard Deviation 509
|
556 h*ng/mL
Standard Deviation 397
|
760 h*ng/mL
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
STA-5944 - Day 8
|
653 h*ng/mL
Standard Deviation 365
|
2070 h*ng/mL
Standard Deviation 1430
|
1810 h*ng/mL
Standard Deviation 1240
|
1860 h*ng/mL
Standard Deviation 1160
|
1320 h*ng/mL
Standard Deviation 211
|
1350 h*ng/mL
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
STA-5908 - Day 8
|
433 h*ng/mL
Standard Deviation 195
|
1140 h*ng/mL
Standard Deviation 818
|
1360 h*ng/mL
Standard Deviation 796
|
1270 h*ng/mL
Standard Deviation 875
|
1040 h*ng/mL
Standard Deviation 572
|
690 h*ng/mL
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
STA-6048 - Day 1
|
238 h*ng/mL
Standard Deviation 91.2
|
280 h*ng/mL
Standard Deviation 216
|
622 h*ng/mL
Standard Deviation 372
|
443 h*ng/mL
Standard Deviation 325
|
785 h*ng/mL
Standard Deviation 923
|
869 h*ng/mL
Standard Deviation 415
|
—
|
—
|
SECONDARY outcome
Timeframe: 1 cycle (28 days) up to a maximum of 24 cyclesPopulation: Full Analysis Set: All participants who received ≥1 dose of study drug.
Anti-tumor response as assessed by investigator according to modified Hallek or Lugano Response Criteria by Disease Type and Cohort
Outcome measures
| Measure |
All Participants
n=3 Participants
All participants who received at least 1 dose of LAM-002A, either at 50 mg BID, 100 mg BID, 150 mg BID, 75 mg TID, or 125 mg BID.
|
LAM-002A Continuous Monotherapy - 75 mg TID
n=8 Participants
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
n=5 Participants
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg BID
n=4 Participants
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
n=3 Participants
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg
n=20 Participants
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
n=12 Participants
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
n=7 Participants
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
|---|---|---|---|---|---|---|---|---|
|
Objective Response Rate
FL (follicular lymphoma)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
5 Participants
|
2 Participants
|
|
Objective Response Rate
MZL (marginal zone lymphoma)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Objective Response Rate
MCL (mantle cell lymphoma)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Objective Response Rate
CLL/SLL (chronic lymphocytic leukemia/ small lymphocytic lymphoma)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Objective Response Rate
DLBCL (diffuse large B-cell lymphoma)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
Adverse Events
LAM-002A Continuous Monotherapy - 50 mg BID
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LAM-002A Continuous Monotherapy - 100 mg BID
Serious events: 3 serious events
Other events: 8 other events
Deaths: 1 deaths
LAM-002A Continuous Monotherapy - 150 mg BID
Serious events: 1 serious events
Other events: 5 other events
Deaths: 1 deaths
LAM-002A Continuous Monotherapy - 75 mg TID
Serious events: 2 serious events
Other events: 4 other events
Deaths: 0 deaths
LAM-002A Intermittent Monotherapy - 150 mg BID
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LAM-002A Continuous Monotherapy - 125 mg BID
Serious events: 9 serious events
Other events: 20 other events
Deaths: 3 deaths
LAM-002A + Rituximab
Serious events: 5 serious events
Other events: 12 other events
Deaths: 0 deaths
LAM-002A + Atezolizumab
Serious events: 6 serious events
Other events: 7 other events
Deaths: 3 deaths
Serious adverse events
| Measure |
LAM-002A Continuous Monotherapy - 50 mg BID
n=3 participants at risk
All participants took 50 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
n=8 participants at risk
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
n=5 participants at risk
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 75 mg TID
n=4 participants at risk
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg BID
n=3 participants at risk
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg BID
n=20 participants at risk
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
n=12 participants at risk
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
n=7 participants at risk
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Number of events 2 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Disease progression
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Fatigue
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Lung infection
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumocystis jirovecii pneumonia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Syncope
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Number of events 2 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Number of events 2 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Platelet count decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Compartment syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Number of events 2 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood sodium decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Number of events 1 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
Other adverse events
| Measure |
LAM-002A Continuous Monotherapy - 50 mg BID
n=3 participants at risk
All participants took 50 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 100 mg BID
n=8 participants at risk
All participants took 100 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 150 mg BID
n=5 participants at risk
All participants took 150 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 75 mg TID
n=4 participants at risk
All participants took 75 mg LAM-002A three times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Intermittent Monotherapy - 150 mg BID
n=3 participants at risk
All participants received LAM-002A at 150 mg two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A Continuous Monotherapy - 125 mg BID
n=20 participants at risk
All participants took 125 mg LAM-002A two times daily by mouth every day until cancer progression or intolerability.
LAM-002A: 25 mg capsules or 50 mg capsules
|
LAM-002A + Rituximab
n=12 participants at risk
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab by vein (IV) every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions) or one dose of rituximab IV followed by rituximab subcutaneous (SC) for 3 weeks and then SC every 8 weeks for 4 times (total of 8 doses).
Rituximab: 375 mg/m\^2 IV or rituximab (hyaluronidase) (1,400 mg rituximab and 23,400 Units hyaluronidase human) SC
|
LAM-002A + Atezolizumab
n=7 participants at risk
All participants received LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Atezolizumab: 1200 mg by vein
|
|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
37.5%
3/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
60.0%
3/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
75.0%
3/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
45.0%
9/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
6/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
85.7%
6/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Diarrhoea
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
40.0%
2/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
66.7%
2/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
30.0%
6/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
6/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
60.0%
3/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
75.0%
3/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
4/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
3/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
57.1%
4/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
2/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
71.4%
5/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
5/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Anal incontinence
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Dental caries
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Hyperchlorhydria
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Retching
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Sensitivity of teeth
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Gastrointestinal disorders
Tooth disorder
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Fatigue
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
4/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
40.0%
2/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
10/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
58.3%
7/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Asthenia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
5/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Oedema peripheral
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Chills
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
2/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Disease progression
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Gait disturbance
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Eye complication associated with device
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Adverse drug reaction
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Chest pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Face oedema
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Injection site bruising
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Oedema
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Peripheral swelling
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Pyrexia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
42.9%
3/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Influenza like illness
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Hemoglobin decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
37.5%
3/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
5/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood sodium decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
2/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
40.0%
2/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
4/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Platelet count decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
37.5%
3/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
2/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood potassium decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
40.0%
2/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
60.0%
3/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Weight decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood glucose increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood albumin decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood calcium decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood glucose decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood phosphorus increased
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
40.0%
2/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Ammonia increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood cholesterol increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Weight increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood lactic acid increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood magnesium decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood potassium increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood sodium increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Cardiac murmur
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
White blood cell count increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood calcium increased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Investigations
Blood phosphorus decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
2/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
4/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Headache
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
40.0%
2/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
3/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
3/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
42.9%
3/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Restless legs syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Seizure
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Dysarthria
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Syncope
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Ageusia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Asterixis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Ataxia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Hepatic encephalopathy
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Hyperaesthesia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Nervous system disorders
Spinal cord compression
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Candida infection
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Tooth abscess
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
2/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Lung infection
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Oesophageal candidiasis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Pneumocystis jirovecii pneumonia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Salmonellosis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Upper respiratory tract infection
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
3/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Eye infection
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Infections and infestations
Vulvovaginitis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
2/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
4/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
3/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Compartment syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
40.0%
8/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
3/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
4/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Iron deficiency
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Malnutrition
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Metabolism and nutrition disorders
Vitamin K deficiency
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
50.0%
2/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
15.0%
3/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
4/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Lung infiltration
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
40.0%
2/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
66.7%
2/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
28.6%
2/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
16.7%
2/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Vascular disorders
Hot flush
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Vascular disorders
Hypovolaemic shock
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
4/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
3/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
10.0%
2/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Right ventricular enlargement
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Sinus arrhythmia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
3/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Injury, poisoning and procedural complications
Wound secretion
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of liver
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Eye disorders
Cataract
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
20.0%
1/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Eye disorders
Eye pain
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Eye disorders
Vision blurred
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Eye disorders
Diplopia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Eye disorders
Eyelid ptosis
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
14.3%
1/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Ear and labyrinth disorders
Ear discomfort
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Endocrine disorders
Hypercalcaemia of malignancy
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Hepatobiliary disorders
Jaundice cholestatic
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
5.0%
1/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Immune system disorders
Hypogammaglobulinaemia
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
12.5%
1/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
33.3%
1/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
|
Surgical and medical procedures
Sinus operation
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/8 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/5 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
25.0%
1/4 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/3 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/20 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
8.3%
1/12 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
0.00%
0/7 • Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.
Adverse Events were analyzed for all participants who received at least 1 dose of study treatment.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place